Home
About
Directory
Promoted Listings
Purchase Data
Drug Pipelines
Data Licensing
Newsletter
Contact
Custopharm
is defunct.
Acquired by Hikma, Apr 2022, $375M + $50M milestones
------------------
If you believe any of this information is incorrect, please
let us know
.